Apotrem SRL
The score of Apotrem shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -52 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apotrem's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −80,844 € | ||||
| Equity | 18,824 € | ||||
| Cash | 47,384 € | ||||
| EBITDA | −25,647 € | ||||
| Total assets | 110,282 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jun 2026
- Year ended 31 Dec 2024filed on 05 May 2025
- Year ended 31 Dec 2023filed on 05 Jul 2024
- Year ended 31 Dec 2022filed on 17 Jul 2023
- Year ended 31 Dec 2021filed on 01 Jul 2022
Apotrem's financial analysis
- Solvency17.1%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apotrem
Apotrem's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0668.809.159
- VAT number
- BE0668809159
- Peppol
- Registered · 0208:0668809159 · as of 06 Nov 2026
- Legal form
- SRL
- Incorporated
- 06 Jan 2017
- Registered office
- 3120 Tremelo
- Latest accounts
- 2025 · filed on 09 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apotrem (SRL) has been based in Tremelo since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 80,844 € and equity of 18,824 €; its revenue is not published. Its solvency stands at 17.1%, below the median of its sector (44.2%).
Companies similar to Apotrem
Companies in the same business, of comparable size and area, outside its group.
- Heck Pharma Retail sale of pharmaceutical products Büllingen · balance sheet 522,168 €
- Pharmacie Bailly Retail sale of pharmaceutical products Ellezelles · balance sheet 93,414 €
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Curasan Retail sale of pharmaceutical products Zwalm · balance sheet 103,974 €
- BSB Pharma Retail sale of pharmaceutical products Berchem-Sainte-Agathe · balance sheet 118,927 €
- Mine - Energy Wholesale of pharmaceutical and medical goods Herzele · balance sheet 170,859 €
- Panax Retail sale of pharmaceutical products Wemmel · balance sheet 99,320 €
- Apocurae Retail sale of pharmaceutical products Kortemark · balance sheet 124,948 €
Frequently asked questions about Apotrem
What is the revenue of Apotrem?
Apotrem files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apotrem?
In Belgium, the VAT number is the company number prefixed with BE: BE0668809159 for Apotrem, if the company is VAT-registered. Its company number (CBE) is 0668.809.159.
Where is the registered office of Apotrem?
According to the CBE register, the registered office of Apotrem is in 3120 Tremelo.
What is the equity of Apotrem?
At the close of the 2025 financial year, the equity of Apotrem amounts to 18,824 €, a solvency of 17.1% of total assets.
Who manages Apotrem?
The register lists 4 active mandates at Apotrem. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apotrem
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →